Application of CBNAAT (Xpert MTB/RIF assay) in new smear negative pulmonary tuberculosis patients

TB in sputum.Courtesy of Centers for Disease Control and Prevention's Public Health Image Library
Submitted: August 10, 2019
Accepted: January 2, 2020
Published: February 27, 2020
Abstract Views: 1396
PDF: 687
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Presumptive pulmonary tuberculosis (PTB) patients whose sputum are detected to be smear negative for acid fast bacilli (AFB) present a significant challenge for a treating physician. Initiating these patients on anti tuberculous treatment (ATT) on empirical basis is not a good strategy as many were found to be sputum culture for tuberculosis negative on further evaluation according to many previous studies. In India due to resource limited settings and lack of knowledge about newest diagnostic modalities patients are often initiated only on the basis of characteristic clinical symptoms and chest radiographic abnormalities. This study was conducted to identify the advantage of application of sputum cartridge based nucleic acid amplification test (CBNAAT) in sputum AFB smear negative presumptive pulmonary TB patients. Our study concluded that clinical symptoms and radiological characteristics cannot differentiate TB patients from non-TB patients. Treating patients only on empirical basis would have resulted in unnecessary treatment of 41 patients.



PlumX Metrics


Download data is not yet available.


How to Cite

Chopra, Vishal, Baljeet Singh Virk, Siddharth Chopra, Monika Bansal, and Jain Chungath. 2020. “Application of CBNAAT (Xpert MTB/RIF Assay) in New Smear Negative Pulmonary Tuberculosis Patients”. Monaldi Archives for Chest Disease 90 (1).